Dosing and uses of Optiray (ioversol)
Adult dosage forms and strengths
injectable solution
- 160mg/mL
- 240mg/mL
- 300mg/mL
- 320mg/mL
- 350mg/mL
Radiographic Body Imaging
Usual: 50-150 mL IV OR 100-250 mL IV of (240 mg/mL)
25-75 mL IV OR 50-150 mL IV infusion; not to exceed 150 mL
For 240 mg/mL: 35-100 mL IV OR 70-200 mL IV infusion; not to exceed 250 mL
IV-DSa
30-50 mL IV, repeat PRN; NMT 250 mL
Administration
- Central catheter: inject at 10-30 mL/sec
- Peripheral: inject at 12-20 mL/sec
- Flush vein immediately after injection w/ 20-25 mL of NS or D5W
IV Urography
50-75 mL IV Or
75-100 mL IV of (240 mg/mL)
Higher dosages may be indicated
- 1.4 mL/kg IV of 350 mg/mL; not to exceed 140 mL, OR
- 1.5-2 mL/kg IV of 320 mg/mL; not to exceed 150 mL, OR
- 1.5 mL/kg IV of 300 mg/mL; not to exceed 150 mL, OR
- 2 mL/kg IV of 240 mg/mL; not to exceed 200 mL
Preparatory dehydration may contribute to ARF
Other Indications & Uses
Peripheral/cerebral/coronary/visceral/renal arteriography, venography, aortography, & left ventriculography coronary, contrast enhanced computed tomographic imaging of head/body, IV excretory urography, IV digital subtraction angiography/venography, cardiovascular system angiography, intra-arterial digital subtraction angiography (IA-DSA)
Pediatric dosage forms and strengths
injectable solution
- 160mg/mL
- 240mg/mL
- 300mg/mL
- 320mg/mL
- 350mg/mL
Radiographic Body Imaging
1-3 mL/kg IV (usual: 2 mL/kg)
IV Urography
0.5-3 mL/kg IV (usual 1-1.5 mL/kg); not to exceed 3 mL/kg
Warnings
Contraindications
Not for intrathecal use (may cause death, convulsions, cerebral hemorrhage, coma, paralysis, ARF)
For procedural contraindications see package insert
Cautions
Inhibits blood coagulation
Severe renal impairment, combined renal/hepatic disease, severe thyrotoxicosis, myelomatosis, anuria, pheochromocytoma, sickle cell, CHF, severe arterial/venous disease
May cause renal failure in pts w/ advanced vascular disease, diabetes; should be well hydrated before/after procedure
Hypersensitivity to contrast medium, iodine
Allergies (bronchial asthma, hay fever, food allergies)
Pregnancy and lactation
Pregnancy category: B
Lactation: not known, use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Optiray (ioversol)
Distribution: wide
Excretion: urine
